Rocket Pharmaceuticals, Inc. (RCKT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Rocket Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Rocket Pharmaceuticals, Inc. (RCKT) has returned 1.99% so far this year and -46.33% over the past 12 months. Over the last ten years, RCKT has returned -19.29% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Feb 18, 2015, RCKT's average daily return is +0.11%, while the average monthly return is +1.73%. At this rate, your investment would double in approximately 3.4 years.

Historically, 49% of months were positive and 51% were negative. The best month was Jul 2015 with a return of +165.1%, while the worst month was Jan 2017 at -73.8%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 8 months.

On a daily basis, RCKT closed higher 48% of trading days. The best single day was Jul 23, 2015 with a return of +193.9%, while the worst single day was Jan 3, 2017 at -71.3%.

Rocket Pharmaceuticals, Inc. has an annualized alpha of 11.63%, beta of 1.44, and R² of 0.06 versus S&P 500 Index. Calculated based on daily prices since February 19, 2015.

• This stock participated in 178.61% of S&P 500 Index downside but only 69.40% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.06 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RCKT ranks 25 for risk / return — below 25% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Rocket Pharmaceuticals, Inc. (RCKT) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Rocket Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Rocket Pharmaceuticals, Inc. was 96.70%, occurring on May 27, 2025. The portfolio has not yet recovered.

The current Rocket Pharmaceuticals, Inc. drawdown is 94.93%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Rocket Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Rocket Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.